 Brianne Bettcher
Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 29 | 2025 | 574 | 5.980 |
Why?
| | White Matter | 8 | 2023 | 144 | 2.730 |
Why?
| | Cognition Disorders | 13 | 2023 | 510 | 1.790 |
Why?
| | Aging | 19 | 2025 | 1860 | 1.730 |
Why?
| | Neuropsychological Tests | 26 | 2025 | 1054 | 1.640 |
Why?
| | Memory, Episodic | 4 | 2021 | 52 | 1.370 |
Why?
| | Dementia | 10 | 2024 | 264 | 1.350 |
Why?
| | Cognition | 11 | 2023 | 1179 | 1.300 |
Why?
| | Activities of Daily Living | 8 | 2021 | 419 | 1.300 |
Why?
| | Inflammation | 7 | 2025 | 2858 | 1.270 |
Why?
| | Cognitive Dysfunction | 12 | 2025 | 391 | 1.250 |
Why?
| | Aged, 80 and over | 37 | 2025 | 7698 | 1.120 |
Why?
| | Executive Function | 10 | 2021 | 453 | 1.120 |
Why?
| | Psychomotor Performance | 7 | 2021 | 316 | 1.070 |
Why?
| | Signal Detection, Psychological | 3 | 2011 | 24 | 1.000 |
Why?
| | Gliosis | 2 | 2023 | 28 | 0.900 |
Why?
| | Aged | 53 | 2025 | 24236 | 0.890 |
Why?
| | Brain | 14 | 2024 | 2790 | 0.850 |
Why?
| | Neurology | 1 | 2025 | 111 | 0.820 |
Why?
| | Biomarkers | 9 | 2025 | 4115 | 0.810 |
Why?
| | Encephalitis | 3 | 2014 | 136 | 0.810 |
Why?
| | Inflammation Mediators | 1 | 2025 | 513 | 0.740 |
Why?
| | Memory Consolidation | 1 | 2021 | 13 | 0.720 |
Why?
| | Biofeedback, Psychology | 2 | 2011 | 37 | 0.700 |
Why?
| | Atrophy | 8 | 2024 | 189 | 0.670 |
Why?
| | Healthy Aging | 1 | 2021 | 36 | 0.670 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 102 | 0.670 |
Why?
| | Temporal Lobe | 4 | 2021 | 102 | 0.650 |
Why?
| | Diffusion Tensor Imaging | 5 | 2023 | 76 | 0.650 |
Why?
| | Memory, Short-Term | 4 | 2019 | 257 | 0.650 |
Why?
| | Immune System | 1 | 2021 | 181 | 0.650 |
Why?
| | Fornix, Brain | 1 | 2019 | 6 | 0.630 |
Why?
| | Cognitive Reserve | 1 | 2019 | 15 | 0.620 |
Why?
| | Neurogenesis | 1 | 2021 | 153 | 0.600 |
Why?
| | Astrocytes | 1 | 2021 | 217 | 0.590 |
Why?
| | Memory | 7 | 2014 | 258 | 0.580 |
Why?
| | Neurodegenerative Diseases | 2 | 2012 | 138 | 0.580 |
Why?
| | Frontotemporal Dementia | 4 | 2024 | 57 | 0.570 |
Why?
| | Anisotropy | 5 | 2021 | 77 | 0.550 |
Why?
| | Autoimmune Diseases of the Nervous System | 2 | 2014 | 29 | 0.540 |
Why?
| | Corpus Callosum | 2 | 2014 | 70 | 0.530 |
Why?
| | Memory Disorders | 2 | 2017 | 176 | 0.520 |
Why?
| | Middle Aged | 36 | 2025 | 33864 | 0.520 |
Why?
| | Magnetic Resonance Imaging | 19 | 2024 | 3651 | 0.500 |
Why?
| | Surgical Procedures, Operative | 1 | 2019 | 263 | 0.500 |
Why?
| | Humans | 70 | 2025 | 139062 | 0.500 |
Why?
| | Potassium Channels, Voltage-Gated | 3 | 2014 | 51 | 0.480 |
Why?
| | Male | 50 | 2025 | 68324 | 0.460 |
Why?
| | Interleukin-6 | 3 | 2018 | 786 | 0.450 |
Why?
| | Cholesterol | 1 | 2017 | 401 | 0.450 |
Why?
| | Female | 48 | 2025 | 74074 | 0.440 |
Why?
| | Language Disorders | 1 | 2014 | 30 | 0.440 |
Why?
| | Prefrontal Cortex | 1 | 2016 | 307 | 0.390 |
Why?
| | C-Reactive Protein | 2 | 2014 | 411 | 0.390 |
Why?
| | Brain Mapping | 1 | 2016 | 524 | 0.390 |
Why?
| | Environment | 2 | 2011 | 341 | 0.370 |
Why?
| | Cerebral Cortex | 3 | 2022 | 452 | 0.360 |
Why?
| | Dementia, Vascular | 2 | 2008 | 20 | 0.350 |
Why?
| | tau Proteins | 6 | 2023 | 95 | 0.350 |
Why?
| | Diffusion Magnetic Resonance Imaging | 3 | 2023 | 154 | 0.330 |
Why?
| | Task Performance and Analysis | 1 | 2011 | 190 | 0.330 |
Why?
| | Cohort Studies | 9 | 2020 | 5736 | 0.290 |
Why?
| | Reproducibility of Results | 6 | 2025 | 3316 | 0.290 |
Why?
| | Mental Status Schedule | 4 | 2016 | 33 | 0.280 |
Why?
| | Exosomes | 2 | 2020 | 106 | 0.280 |
Why?
| | Verbal Learning | 4 | 2019 | 66 | 0.280 |
Why?
| | Frontal Lobe | 2 | 2019 | 160 | 0.240 |
Why?
| | Apolipoproteins E | 4 | 2021 | 92 | 0.230 |
Why?
| | Cognitive Aging | 2 | 2023 | 15 | 0.230 |
Why?
| | Body Mass Index | 1 | 2013 | 2388 | 0.230 |
Why?
| | DNA Transposable Elements | 1 | 2025 | 122 | 0.220 |
Why?
| | Pilot Projects | 2 | 2021 | 1763 | 0.220 |
Why?
| | Video Recording | 1 | 2025 | 180 | 0.210 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2024 | 10 | 0.210 |
Why?
| | Predictive Value of Tests | 3 | 2017 | 2044 | 0.210 |
Why?
| | Neurites | 1 | 2023 | 47 | 0.200 |
Why?
| | Neuroimaging | 2 | 2023 | 263 | 0.200 |
Why?
| | Cross-Over Studies | 1 | 2025 | 553 | 0.190 |
Why?
| | Risk Factors | 5 | 2020 | 10426 | 0.190 |
Why?
| | Blood-Brain Barrier | 1 | 2023 | 140 | 0.180 |
Why?
| | Cross-Sectional Studies | 6 | 2021 | 5537 | 0.180 |
Why?
| | Central Nervous System | 1 | 2023 | 266 | 0.170 |
Why?
| | Amnesia | 4 | 2014 | 46 | 0.170 |
Why?
| | Apolipoprotein E4 | 1 | 2021 | 37 | 0.170 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 648 | 0.170 |
Why?
| | Ultracentrifugation | 1 | 2020 | 52 | 0.170 |
Why?
| | Reaction Time | 2 | 2015 | 421 | 0.160 |
Why?
| | Sleep, REM | 1 | 2020 | 34 | 0.160 |
Why?
| | Proteins | 3 | 2016 | 1014 | 0.160 |
Why?
| | Longevity | 1 | 2021 | 174 | 0.160 |
Why?
| | Medication Therapy Management | 1 | 2021 | 77 | 0.160 |
Why?
| | Computational Biology | 1 | 2024 | 650 | 0.160 |
Why?
| | Attention | 2 | 2016 | 442 | 0.160 |
Why?
| | Speech Disorders | 1 | 2019 | 31 | 0.160 |
Why?
| | Lewy Body Disease | 1 | 2020 | 30 | 0.150 |
Why?
| | Hearing Loss | 1 | 2023 | 219 | 0.150 |
Why?
| | Software | 1 | 2024 | 668 | 0.150 |
Why?
| | Leukoaraiosis | 2 | 2009 | 2 | 0.150 |
Why?
| | Advance Care Planning | 1 | 2022 | 221 | 0.150 |
Why?
| | Myelin Sheath | 1 | 2021 | 166 | 0.150 |
Why?
| | Electroencephalography | 1 | 2021 | 444 | 0.150 |
Why?
| | Gray Matter | 1 | 2019 | 81 | 0.150 |
Why?
| | Chemokine CCL3 | 1 | 2018 | 16 | 0.140 |
Why?
| | Chemokine CCL4 | 1 | 2018 | 23 | 0.140 |
Why?
| | Myocardial Contraction | 1 | 2020 | 303 | 0.140 |
Why?
| | Educational Status | 1 | 2021 | 474 | 0.140 |
Why?
| | Severity of Illness Index | 9 | 2016 | 2864 | 0.140 |
Why?
| | Psychiatric Status Rating Scales | 3 | 2017 | 560 | 0.140 |
Why?
| | Research | 1 | 2021 | 452 | 0.140 |
Why?
| | Hippocampus | 2 | 2021 | 929 | 0.140 |
Why?
| | Neurogranin | 1 | 2017 | 2 | 0.140 |
Why?
| | Primary Progressive Nonfluent Aphasia | 2 | 2013 | 2 | 0.130 |
Why?
| | Functional Laterality | 2 | 2019 | 232 | 0.130 |
Why?
| | Cytokines | 2 | 2018 | 2084 | 0.130 |
Why?
| | Mental Recall | 3 | 2017 | 206 | 0.130 |
Why?
| | Algorithms | 1 | 2024 | 1722 | 0.130 |
Why?
| | Autoantibodies | 2 | 2014 | 1454 | 0.130 |
Why?
| | Regression Analysis | 3 | 2020 | 1015 | 0.130 |
Why?
| | Neuropsychiatry | 1 | 2016 | 17 | 0.130 |
Why?
| | Time Factors | 3 | 2014 | 6885 | 0.130 |
Why?
| | Hypolipidemic Agents | 1 | 2017 | 90 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2018 | 1248 | 0.120 |
Why?
| | Heart Rate | 1 | 2020 | 798 | 0.120 |
Why?
| | Random Allocation | 1 | 2017 | 364 | 0.120 |
Why?
| | Telemedicine | 1 | 2025 | 867 | 0.120 |
Why?
| | Chemokine CCL11 | 1 | 2015 | 27 | 0.120 |
Why?
| | Models, Anatomic | 1 | 2016 | 84 | 0.120 |
Why?
| | Amyloid | 1 | 2016 | 94 | 0.110 |
Why?
| | Factor Analysis, Statistical | 1 | 2016 | 294 | 0.110 |
Why?
| | Plaque, Amyloid | 1 | 2014 | 18 | 0.110 |
Why?
| | Sleep | 1 | 2021 | 800 | 0.110 |
Why?
| | Triglycerides | 1 | 2017 | 515 | 0.110 |
Why?
| | Models, Neurological | 2 | 2024 | 248 | 0.110 |
Why?
| | Nanoparticles | 1 | 2020 | 469 | 0.110 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2014 | 66 | 0.110 |
Why?
| | Prodromal Symptoms | 1 | 2014 | 17 | 0.110 |
Why?
| | Carotid Artery Diseases | 1 | 2014 | 61 | 0.110 |
Why?
| | Communication | 1 | 2021 | 932 | 0.110 |
Why?
| | Parkinson Disease | 2 | 2012 | 552 | 0.110 |
Why?
| | Retina | 1 | 2016 | 303 | 0.110 |
Why?
| | Bradycardia | 1 | 2014 | 53 | 0.110 |
Why?
| | Aphasia, Broca | 1 | 2013 | 3 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 96 | 0.110 |
Why?
| | Aphasia, Primary Progressive | 1 | 2013 | 2 | 0.110 |
Why?
| | Creutzfeldt-Jakob Syndrome | 1 | 2013 | 19 | 0.100 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 5892 | 0.100 |
Why?
| | Frontotemporal Lobar Degeneration | 1 | 2013 | 18 | 0.100 |
Why?
| | Proteomics | 1 | 2020 | 1114 | 0.100 |
Why?
| | Residence Characteristics | 1 | 2017 | 366 | 0.100 |
Why?
| | Prions | 1 | 2013 | 51 | 0.100 |
Why?
| | Language Development Disorders | 1 | 2013 | 39 | 0.100 |
Why?
| | Pacemaker, Artificial | 1 | 2014 | 116 | 0.100 |
Why?
| | Brain Diseases | 1 | 2014 | 148 | 0.100 |
Why?
| | Point Mutation | 1 | 2013 | 239 | 0.100 |
Why?
| | Hypercholesterolemia | 1 | 2013 | 104 | 0.100 |
Why?
| | Colorado | 1 | 2022 | 4532 | 0.090 |
Why?
| | Disease Progression | 2 | 2017 | 2741 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2014 | 243 | 0.090 |
Why?
| | Linear Models | 1 | 2014 | 856 | 0.090 |
Why?
| | Animals | 3 | 2023 | 37351 | 0.090 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2016 | 755 | 0.090 |
Why?
| | Apraxias | 3 | 2019 | 6 | 0.090 |
Why?
| | Down Syndrome | 1 | 2017 | 486 | 0.080 |
Why?
| | Statistics as Topic | 1 | 2011 | 299 | 0.080 |
Why?
| | Glucose | 1 | 2016 | 1032 | 0.080 |
Why?
| | Adult | 6 | 2023 | 38389 | 0.080 |
Why?
| | Comprehension | 2 | 2012 | 175 | 0.080 |
Why?
| | Macrophages | 1 | 2018 | 1545 | 0.080 |
Why?
| | Psychomotor Disorders | 1 | 2010 | 13 | 0.080 |
Why?
| | Disability Evaluation | 2 | 2009 | 298 | 0.080 |
Why?
| | Stress, Psychological | 1 | 2018 | 1124 | 0.080 |
Why?
| | Serial Learning | 1 | 2009 | 8 | 0.080 |
Why?
| | Learning | 1 | 2013 | 420 | 0.080 |
Why?
| | Hypertension | 2 | 2020 | 1251 | 0.080 |
Why?
| | Longitudinal Studies | 4 | 2020 | 2846 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2017 | 961 | 0.080 |
Why?
| | Age Factors | 1 | 2017 | 3273 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2369 | 0.080 |
Why?
| | Neurons | 1 | 2018 | 1606 | 0.070 |
Why?
| | Motor Skills | 1 | 2009 | 100 | 0.070 |
Why?
| | Choice Behavior | 1 | 2010 | 173 | 0.070 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2008 | 48 | 0.070 |
Why?
| | Amyloid beta-Peptides | 2 | 2023 | 233 | 0.070 |
Why?
| | Language | 2 | 2008 | 303 | 0.070 |
Why?
| | Cluster Analysis | 2 | 2024 | 515 | 0.070 |
Why?
| | Prospective Studies | 3 | 2014 | 7660 | 0.070 |
Why?
| | Goals | 1 | 2009 | 174 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 2144 | 0.070 |
Why?
| | Semantics | 1 | 2008 | 95 | 0.070 |
Why?
| | Mental Disorders | 1 | 2016 | 1091 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 15922 | 0.070 |
Why?
| | Young Adult | 2 | 2021 | 13341 | 0.070 |
Why?
| | Cues | 1 | 2009 | 319 | 0.060 |
Why?
| | Insulin Resistance | 1 | 2015 | 1225 | 0.060 |
Why?
| | Peptide Fragments | 2 | 2023 | 695 | 0.060 |
Why?
| | Health Status | 1 | 2011 | 821 | 0.060 |
Why?
| | Dopamine | 1 | 2009 | 309 | 0.060 |
Why?
| | Smoking | 1 | 2013 | 1607 | 0.060 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2006 | 66 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 856 | 0.050 |
Why?
| | Antipsychotic Agents | 1 | 2006 | 205 | 0.050 |
Why?
| | Analysis of Variance | 3 | 2012 | 1318 | 0.050 |
Why?
| | Psychotic Disorders | 1 | 2006 | 172 | 0.050 |
Why?
| | Amyloidogenic Proteins | 1 | 2023 | 16 | 0.050 |
Why?
| | Adolescent | 2 | 2021 | 21561 | 0.050 |
Why?
| | Cerebral Hemorrhage | 1 | 2024 | 113 | 0.050 |
Why?
| | Schizophrenia | 1 | 2006 | 451 | 0.050 |
Why?
| | Nerve Net | 1 | 2024 | 268 | 0.040 |
Why?
| | Child | 1 | 2021 | 21906 | 0.040 |
Why?
| | Vision Disorders | 1 | 2023 | 156 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2014 | 463 | 0.040 |
Why?
| | Chemical Precipitation | 1 | 2020 | 38 | 0.040 |
Why?
| | DNA Methylation | 1 | 2025 | 638 | 0.040 |
Why?
| | Cardiac Electrophysiology | 1 | 2020 | 18 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 997 | 0.040 |
Why?
| | Diffusion | 1 | 2020 | 121 | 0.040 |
Why?
| | Machine Learning | 1 | 2024 | 520 | 0.040 |
Why?
| | Regional Blood Flow | 1 | 2021 | 498 | 0.040 |
Why?
| | Facial Expression | 1 | 2019 | 76 | 0.040 |
Why?
| | Language Tests | 2 | 2009 | 22 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2021 | 267 | 0.040 |
Why?
| | Problem Solving | 2 | 2009 | 156 | 0.040 |
Why?
| | Immunoassay | 1 | 2018 | 112 | 0.030 |
Why?
| | Nerve Degeneration | 1 | 2016 | 49 | 0.030 |
Why?
| | C9orf72 Protein | 1 | 2016 | 12 | 0.030 |
Why?
| | Independent Living | 1 | 2017 | 107 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2018 | 304 | 0.030 |
Why?
| | Carbolines | 1 | 2016 | 32 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2018 | 380 | 0.030 |
Why?
| | Benzothiazoles | 1 | 2016 | 35 | 0.030 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2015 | 55 | 0.030 |
Why?
| | Thiazoles | 1 | 2016 | 127 | 0.030 |
Why?
| | Aniline Compounds | 1 | 2016 | 104 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2016 | 144 | 0.030 |
Why?
| | Judgment | 1 | 2015 | 61 | 0.030 |
Why?
| | Lipoproteins, LDL | 1 | 2015 | 115 | 0.030 |
Why?
| | Tomography, Optical Coherence | 1 | 2016 | 224 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 2014 | 118 | 0.030 |
Why?
| | Antigens, CD20 | 1 | 2014 | 34 | 0.030 |
Why?
| | Photic Stimulation | 1 | 2015 | 251 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2016 | 305 | 0.030 |
Why?
| | Hyponatremia | 1 | 2014 | 42 | 0.030 |
Why?
| | Age of Onset | 1 | 2015 | 519 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 566 | 0.030 |
Why?
| | Visual Perception | 1 | 2015 | 171 | 0.030 |
Why?
| | Fasting | 1 | 2015 | 283 | 0.030 |
Why?
| | Genetic Testing | 1 | 2016 | 457 | 0.030 |
Why?
| | Rituximab | 1 | 2014 | 202 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2013 | 312 | 0.020 |
Why?
| | Pedigree | 1 | 2013 | 513 | 0.020 |
Why?
| | Caregivers | 2 | 2012 | 905 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2012 | 57 | 0.020 |
Why?
| | Seizures | 1 | 2014 | 433 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2016 | 769 | 0.020 |
Why?
| | Genotype | 1 | 2015 | 1873 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2010 | 237 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 1400 | 0.020 |
Why?
| | Blood Pressure | 1 | 2015 | 1735 | 0.020 |
Why?
| | Comorbidity | 1 | 2013 | 1656 | 0.020 |
Why?
| | Differential Threshold | 1 | 2008 | 5 | 0.020 |
Why?
| | Cerebral Ventricles | 1 | 2008 | 54 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3584 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2009 | 221 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2007 | 58 | 0.020 |
Why?
| | Wechsler Scales | 1 | 2007 | 55 | 0.020 |
Why?
| | Reading | 1 | 2008 | 136 | 0.020 |
Why?
| | Speech Perception | 1 | 2008 | 81 | 0.020 |
Why?
| | Quetiapine Fumarate | 1 | 2006 | 25 | 0.020 |
Why?
| | Benchmarking | 1 | 2008 | 184 | 0.020 |
Why?
| | Dibenzothiazepines | 1 | 2006 | 18 | 0.020 |
Why?
| | Risperidone | 1 | 2006 | 29 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1478 | 0.020 |
Why?
| | Blood Glucose | 1 | 2015 | 2191 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 364 | 0.010 |
Why?
| | Mutation | 1 | 2016 | 3999 | 0.010 |
Why?
| | Benzodiazepines | 1 | 2006 | 154 | 0.010 |
Why?
| | Motor Activity | 1 | 2009 | 715 | 0.010 |
Why?
| | Psychometrics | 1 | 2008 | 729 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2006 | 769 | 0.010 |
Why?
| | Outpatients | 1 | 2006 | 416 | 0.010 |
Why?
| | United States | 1 | 2020 | 15065 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2051 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2014 | 10961 | 0.010 |
Why?
| | Depression | 1 | 2007 | 1467 | 0.010 |
Why?
|
|
Bettcher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|